Table of Contents:
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Onychomycosis Market: By Treatment Type
- By Treatment Type Market Size & Forecast
- Oral Antifungals Market Size & Forecast
- Topical Antifungals Market Size & Forecast
- Laser Devices Market Size & Forecast
- Photodynamic Therapy Market Size & Forecast
- Surgical/Chemical Nail Avulsion Market Size & Forecast
- Others Market Size & Forecast
- Chapter 4. Onychomycosis Market: By Route of Administration
- By Route of Administration Market Size & Forecast
- Oral Market Size & Forecast
- Topical Market Size & Forecast
- Injectable Market Size & Forecast
- Others Market Size & Forecast
- Chapter 5. Onychomycosis Market: By Distribution Channel
- By Distribution Channel Market Size & Forecast
- Hospitals & Clinics Market Size & Forecast
- Dermatology Centers Market Size & Forecast
- Retail & Online Pharmacies Market Size & Forecast
- Others Market Size & Forecast
- Chapter 6. Onychomycosis Market: By Infection Type
- By Infection Type Market Size & Forecast
- Distal Subungual Onychomycosis Market Size & Forecast
- White Superficial Onychomycosis Market Size & Forecast
- Proximal Subungual Onychomycosis Market Size & Forecast
- Candidal Onychomycosis Market Size & Forecast
- Total Dystrophic Onychomycosis Market Size & Forecast
- Others Market Size & Forecast
- Chapter 7. Onychomycosis Market: By Causative Agent
- By Causative Agent Market Size & Forecast
- Dermatophytes Market Size & Forecast
- Non-Dermatophyte Molds Market Size & Forecast
- Yeasts Market Size & Forecast
- Others Market Size & Forecast
- Chapter 8. Onychomycosis Market: Regional Outlook
- North America Market Size & Forecast
- Europe Market Size & Forecast
- Asia Pacific Market Size & Forecast
- Latin America Market Size & Forecast
- Middle East & Africa Market Size & Forecast
- Chapter 9. Onychomycosis Market: Competitive Landscape
- Bayer
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Sanofi
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Galderma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Valeant Pharma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Kaken Pharmaceutical
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Seikagaku Corporation
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- GlaxoSmithKline
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Merz Pharma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Polichem
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Vyome Biosciences
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Moberg Pharma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Mylan
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Medimetriks Pharmaceuticals
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- NovaBiotics
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Mayne Pharma
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Lumenis
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Biofrontera
- Company Overview
- Financial Overview
- Product Portfolio
- Strategies
- Bayer
- Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Appendix
- About Us
Frequently Asked Questions
The current market size of the Onychomycosis industry is around USD 4.6 billion in 2023.
Rising geriatric population, Increasing prevalence of diabetes, Growing awareness about treatment, Advancements in diagnostics, Shift towards combination therapies, Strong product pipeline
Low diagnosis rates, high treatment costs, failure of monotherapies, need for prolonged treatment duration, adverse effects of antifungals, patient non-compliance, generic competition, reimbursement challenges, lack of curative therapies, social stigma surrounding nail disorders, limited awareness about treatment options.
The leading component segment in the Onychomycosis Market is oral antifungals.
Bayer, Pfizer, Novartis, Johnson & Johnson, Valeant Pharma, Galderma, Kaken Pharmaceutical, GlaxoSmithKline, Merz Pharma, Vyome Biosciences, Moberg Pharma, Polichem, Medimetriks Pharmaceuticals, NovaBiotics, Mayne Pharma, Lumenis, Biofrontera.
The Onychomycosis Market is projected to reach USD 6.9 billion by 2031 from USD 4.6 billion in 2023, at a CAGR of 5.2% during the forecast period.
Rising geriatric population, Increasing diabetes prevalence, Growing awareness about treatment options, Advancements in diagnostics.